StocksMedium•12 November 2026•
1 min read
Cytosorbents Q3 Revenue Misses Estimates as Losses Continue
Key Facts
1Cytosorbents reported a Non-GAAP EPS of -$0.48 for the quarter.
2Company revenue reached $9.73M, missing analyst estimates by $0.18M.
Cytosorbents reported a Non-GAAP loss per share of $0.48 for the third quarter. According to Seeking Alpha, the company's revenue reached $9.73 million, missing analyst expectations by a margin of $0.18 million.
CTSO closed at $5.34 on November 11, 2026, after trading between a session low of $5.26 and a high of $5.93. The revenue shortfall highlights ongoing challenges for the healthcare company as it failed to meet consensus market estimates for the period.